Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152574 | 1.00 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL4147353 | 1.00 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL4607755 | 1.00 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL7169835 | 1.00 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL4152571 | 1.00 | UGT2B7 (0.45) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL9821111 | 0.98 | UGT2B7 (0.44) | UGT2B7CYP1A2EPHX1APLNRSLC1A2 | |
| SCHEMBL28166839 | 0.85 | UGT2B7 (0.35) | UGT2B7CYP1A2EPHX1CA1CA2 | |
| SCHEMBL4606059 | 0.83 | UGT2B7 (0.34) | UGT2B7CYP1A2EPHX1CA1CA2 | |
| SCHEMBL4605622 | 0.83 | UGT2B7 (0.34) | UGT2B7CYP1A2EPHX1CA1CA2 | |
| SCHEMBL21441575 | 0.83 | UGT2B7 (0.34) | UGT2B7CYP1A2EPHX1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347035-B1 | Isomer composition containing optically active ethyl trans-2,2,6-trimethylcyclohexylcarboxylate and fragrance composition containing the isomer composition | TAKASAGO PERFUMERY CO LTD (JP) | 2008-07-23 | — | — | EP | claimed |
| US-20030207789-A1 | Isomer composition containing optically active ethyl trans-2,2,6-trimethylcyclohexylcarboxylate and fragrance composition containing the isomer composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-11-06 | — | — | US | claimed |
| EP-1347035-A2 | Isomer composition containing optically active ethyl trans-2,2,6-trimethylcyclohexylcarboxylate and fragrance composition containing the isomer composition | Takasago International Corporation (JP) | 2003-09-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207789-A1 | Isomer composition containing optically active ethyl trans-2,2,6-trimethylcyclohexylcarboxylate and fragrance composition containing the isomer composition | ETV1, ELP1, TAS1R2 | UGT2B7 3510/4885CYP1A2 851/4885EPHX1 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.